Back to 2025 Abstracts
Perioperative Antibiotics Do Not Reduce Surgical Site Infections after Fat Grafting for Breast Reconstruction
Yizhuo Shen, Samira Glaeser-Khan, Alex Kammien, Vikram Mookerjee, David Colen
Yale School of Medicine, New Haven, CT, United States.
Background: Fat grafting is commonly utilized to enhance outcomes in breast reconstruction. Despite their routine implementation, perioperative antibiotics lack sufficient evidence in reducing rates of surgical site infection (SSI). Leveraging the largest patient cohort to date, this study examines the association between perioperative antibiotics and SSI after fat grafting for breast reconstruction.
Methods: The Epic Cosmos database (Verona, Wisconsin) was queried for patients who underwent fat grafting within one year following breast reconstruction - either implant-based or autologous - from January 2017 through January 2025. SSIs within 30 days were identified using either ICD codes or identification of a new antibiotic prescription starting 7 days or later post-surgery. Perioperative antibiotics, age, body mass index (BMI), diabetes, smoking status, intraoperative intravenous antibiotics, and volume of fat grafted were included for multivariable regression.
Results: We analyzed 12,247 fat grafting procedures (8,416 implant-based, 3,831 autologous). In the implant-based cohort, perioperative antibiotics (OR 1.21, p=0.031), diabetes (OR 1.65, p<0.0001), higher BMI (OR 1.02, p=0.001), and younger age (OR 0.99, p=0.021) were significant risk factors for infection, defined by additional postoperative antibiotic prescriptions. For infections defined by ICD codes, only BMI was significantly associated with SSI (OR 1.04, p=0.001). In the autologous cohort, diabetes was the only significant risk factor for SSI (OR 1.3, p=0.033).
Conclusion: Perioperative antibiotic prescriptions do not decrease SSI after fat grafting in either implant or autologous breast reconstruction patients. However, they are associated with increased additional postoperative antibiotic prescriptions in implant-based breast reconstruction patients. These data suggest reconsidering routine perioperative antibiotic prophylaxis and focusing on patient-specific risk factors.
Table 1. Results from Multivariable Regression
Back to 2025 Abstracts
